Association for Dental Education in Europe

Learning together to improve oral health and quality of life

You are here


Community dentists can play a key role in the prevention and diagnosis of osteonecrosis of the jaw (ONJ) in patients receiving antiresorptive agents

ONJ is a rare complication that can be associated with the use of bone-protecting (antiresporptive) agents that are used for patients with cancer and bone metastases.

Learn more here about the signs and symptoms of ONJ and approaches to manage this condition.

Download leaflet for Clinicians in:


Download leaflet for Dentists in:



Other downloads:
  Medication-related osteonecrosis of the jaw: introducing the MRONJ prevention algorithm
  ONJ - A guide for patients with cancer or multiple myeloma receiving bone-protective therapy
  ONJ - A guide for healthcare professionals and patients
  Benefits of maintaining bone health with bone-protective agents
  Bone-protective therapy and osteonecrosis of the jaw


The content of this page has been sponsored by Amgen.

Amgen has grown to be one of the world's leading independent biotechnology companies that focuses on areas of high unmet medical need and strives for solutions that improve health outcomes and dramatically improve peoples’ lives.

AMGEN Videos

Advice for clinicians
Handling patient questions about ONJ
ONJ and bone-targeted agents
What is ONJ and who is at risk

© ADEE 2019

by Brag, Design & Digital